0001104659-18-055509.txt : 20180906
0001104659-18-055509.hdr.sgml : 20180906
20180906104026
ACCESSION NUMBER: 0001104659-18-055509
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180904
FILED AS OF DATE: 20180906
DATE AS OF CHANGE: 20180906
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sabba Stephen L
CENTRAL INDEX KEY: 0001442372
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33093
FILM NUMBER: 181056913
MAIL ADDRESS:
STREET 1: DORSET MANAGEMENT CORP
STREET 2: 485 UNDERHILL BLVD SUITE 205
CITY: SYOSSET
STATE: NY
ZIP: 11791
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000886163
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770160744
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-550-7500
MAIL ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
a4.xml
4
X0306
4
2018-09-04
0
0000886163
LIGAND PHARMACEUTICALS INC
LGND
0001442372
Sabba Stephen L
DORSET MANAGEMENT CORP
485 UNDERHILL BLVD SUITE 205
SYOSSET
NY
11791
1
0
0
0
Common Stock
2018-09-04
4
M
0
2500
8.58
A
29356
D
Common Stock
2018-09-04
4
M
0
2500
17.88
A
31856
D
Common Stock
2018-09-04
4
S
0
5000
255.05
D
26856
D
Non-Qualified Stock Option (right to buy)
8.58
2018-09-04
4
M
0
2500
0
D
2020-05-25
Common Stock
2500
0
D
Non-Qualified Stock Option (right to buy)
17.88
2018-09-04
4
M
0
2500
0
D
2019-05-29
Common Stock
2500
0
D
The Reporting Person acquired these securities, as represented in Column 4, upon exercise of the options and at their respective per share exercise price reported on Table II, as follows: for the first row on Table I, at an exercise price of $8.58/option set forth on the first row on Table II, and for the second row on Table I, at an exercise price of $17.88/option set forth on the second row on Table II.
These securities, as represented in Column 5, include a grant of 493 restricted shares in a transaction exempt from Section 16b treatment, as originally reported on a Form 4 filed June 21, 2018, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date.
The price reported is based on an average share price from the following transactions: ((100 shares @ $255.64)+(100 shares @ $255.46)+(200 shares @ $255.45)+(200 shares @ $255.26)+(106 shares @ $255.16)+(4,294 shares @ $255.00))/5,000 shares. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and the sale prices for each of the foregoing transactions.
These securities, as represented in Table II, were acquired in transactions exempt from 16b treatment: the options in the first row were originally granted on May 25, 2010 and those in the second row were originally granted on May 29, 2009 (as both were reported, at their respective exercise prices in Column 2 following the Company's stock split, on a Form 4 filed June 6, 2011).
These securities are currently fully vested and exercisable, having vested in twelve successive equal monthly installments upon completion of each calendar month of service beginning as follows: for those on the first row of Table II, on May 25, 2010, and for those on the second row of Table II, on May 29, 2009.
By: /s/Stephen L. Sabba
2018-09-06